Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1219760 10.3389/fphar.2023.1219760 Pharmacology Correction Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis Herrmann et al. 10.3389/fphar.2023.1219760 Herrmann Franziska Elena Hesslinger Christian Wollin Lutz Nickolaus Peter * Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

Edited by: Stefan Brocke, University of Connecticut Health Center, United States

Reviewed by: Paul Mark Epstein, UCONN Health, United States

Robert B. Nelson, MindImmune Therapeutics, Inc., United States

 *Correspondence: Peter Nickolaus, peter.nickolaus@boehringer-ingelheim.com 30 05 2023 2023 14 1219760 09 05 2023 22 05 2023 Copyright © 2023 Herrmann, Hesslinger, Wollin and Nickolaus. 2023 Herrmann, Hesslinger, Wollin and Nickolaus

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis by Herrmann FE, Hesslinger C, Wollin L and Nickolaus P (2022). Front. Pharmacol. 13:838449. doi: 10.3389/fphar.2022.838449 PDE4B IPF lung fibrosis phosphodiesterase cAMP ILDs section-at-acceptance Inflammation Pharmacology

In the original article, there was an error in Table 1 as published. The n numbers given in the legend to Table 1 were only applicable to the first row of the table. The corrected Table 1 and its caption appear below.

Inhibition of human recombinant PDE4 subtypes by BI 1015550 in comparison to roflumilast and its active metabolite Roflu-N-Ox. IC50 values (nmol/L) are given as means from n independent experiments. Cell extracts containing the active site fragments mediated the conversion of 10 µL [3H]cAMP (0.05 µCi in H2O) to AMP resulting in the binding of this radiolabeled molecule to the yttrium silicate SPA beads and the subsequent generation of scintillation events determined using a Wallac Microbeta counter. AMP, adenosine monophosphate; IC50, inhibitory concentration (nM) for half-maximal inhibition; PDE, phosphodiesterase; SPA, scintillation proximity assay.

PDE4A PDE4B2 PDE4C2 PDE4D2
BI 1015550 248 (n = 3) 10 (n = 2) 8,700 (n = 3) 91 (n = 2)
Roflumilast 1.4 (n = 2) 0.6 (n = 12) 12 (n = 2) 0.8 (n = 12)
Roflu-N-Ox 2.8 (n = 1) 1.4 (n = 6) 15 (n = 1) 1.4 (n = 6)

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.